Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Precision Medicine Paves the Way for Advances in Hormone Receptor–Positive Breast Cancer

September 29th 2021

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

Dr. Lustberg Discusses Ongoing Research in Breast Cancer

September 28th 2021

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

September 28th 2021

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

September 28th 2021

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Frontline Pembrolizumab/Chemo Represents New Standard in Metastatic TNBC With PD-L1 CPS ≥10

September 28th 2021

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.

Dr. Harbeck on Key Results From the WSG ADAPT-TP Trial in HER2+, HR+ Breast Cancer

September 24th 2021

Nadia Harbeck, MD, PhD, discusses the key results from the phase 2 WSG ADAPT-TP trial in patients with HER2-positive, hormone receptor–positive early-stage breast cancer.

Dr. Mitri on Developments in HER2+ Breast Cancer

September 24th 2021

Zahi Mitri, MD, MS, discusses developments in the treatment of patients with HER2-positive breast cancer.

Identifying ILD: Symptomology and Work-Up

September 24th 2021

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

An Overview of Interstitial Lung Disease

September 24th 2021

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Giant of Cancer Care Award Goes to Dawn Hershman, MD, for Critical Advancements in Cancer Care Delivery

September 22nd 2021

Dawn Hershman, MD, a leading breast cancer physician-scientist and pioneer in the burgeoning field of cancer care delivery research, has been named to the Giants of Cancer Care Class of 2021.

Dr. Pegram on Unmet Clinical Needs in HER2+ Metastatic Breast Cancer

September 22nd 2021

Mark D. Pegram, MD, discusses unmet clinical needs in HER2-positive metastatic breast cancer.

Multidisciplinary Care in Breast Cancer: Take-Home Messages

September 22nd 2021

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Practical Considerations for Identifying and Managing ILD in Breast Cancer

September 22nd 2021

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer

September 21st 2021

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Tailoring Therapy for Breast Cancer in 2021: Examining and Applying Clinical Lessons

September 21st 2021

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

Biomarkers May Predict Outcomes Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer

September 20th 2021

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

Dr. Rugo on Overall Survival With First-Line Pembrolizumab in Metastatic TNBC

September 19th 2021

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.

Ribociclib/Letrozole Combo Yields Significant OS Benefit in Postmenopausal HR+/HER2- Advanced Breast Cancer

September 19th 2021

The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.

Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2+ Breast Cancer

September 18th 2021

Fam-trastuzumab deruxtecan-nxki demonstrated a clinically meaningful and statistically significant improvement in progression-free survival vs standard of care trastuzumab emtansine for patients with previously treated HER2-positive metastatic breast cancer.

Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib, Improves pCR, EFS in TNBC

September 17th 2021

The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide significantly improved pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer.